Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a US health insurance database.

被引：26

作者：

Swami, Umang

Hong, Agnes

El-Chaar, Nader N.

Nimke, David

Ramaswamy, Krishnan

Bell, Elizabeth J.

Sandin, Rickard

Agarwal, Neeraj

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Astellas Pharma Inc, Northbrook, IL USA

[3] Pfizer Inc, New York, NY USA

[4] Optum, Eden Prairie, MN USA

[5] Pfizer AB, Sollentuna, Sweden

来源：

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.5072

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5072

引用

页数：3